Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer
David S. Hong, Nicole Concin, Ignace B. Vergote et al. · Clinical Cancer Research · 2019
Abstract Purpose: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). Patients and Methods: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. Results: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%−37%]. Median duration of response (DOR) was 4.2 months (range: 1.0+−9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%−43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%−35%), median DOR of 6.0 months (range: 1.0+−9.7), and 6-month PFS rate of 40% (95% CI: 24%−55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. Conclusions: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.
Cited by 135 works. doi:10.1158/1078-0432.ccr-19-2962 Open-access PDF
Authors
- David S. Hong
- Nicole Concin
- Ignace B. Vergote
- Johann Sebastian De Bono
- Brian M. Slomovitz
- Yvette Drew
- Hendrik‐Tobias Arkenau
- Jean-Pascal Machiels
- James F. Spicer
- Martin David Forster
- Nathalie Cornez
- Christine Gennigens
- Melissa Lynne Johnson
- Fiona C. Thistlethwaite
- Reshma A. Rangwala
- Srinivas Ghatta
- Kristian Windfeld
- Jeffrey R. Harris
- Ulrik Lassen
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Improved Survival with Bevacizumab in Advanced Cervical Cancer
- Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
- Topotecan in Squamous Cell Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group
- Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
- An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.